Summary: Using gene editing to boost the production of SOD3 in the choroid plexus reduced oxidative damage to brain tissue and cerebral spinal fluid in mice exposed to methotrexate.
Source: Boston Children’s Hospital
Up to three-quarters of patients receiving cancer chemotherapy suffer from “chemo brain” — a long-term side effect that makes it harder to remember things, maintain attention, and learn new information. When it strikes children, whose brains are still developing, their schoolwork and self-esteem may suffer.
“When we meet with parents and talk about the life-saving therapy we are proposing for their child’s cancer, one of the most distressing potential side effects we sometimes describe is cognitive loss,” says pediatric oncologist Lisa Diller, MD, chief medical officer for the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
“If we had preventive treatments that could be delivered during therapy, or later in the survivorship phase of care, that would be game-changing.”
In a study published in the journal Neuron on September 6, collaborators Maria Lehtinen, PhD and Naama Kanarek, PhD, in the Department of Pathology at Boston Children’s Hospital, take a first step in that direction. Their vision: treating the cerebrospinal fluid (CSF) that bathes the brain and spinal cord to protect the brain from chemotherapy’s toxic effects.
“If we can treat the CSF, which is easy to target, we can potentially treat the brain itself,” says Kanarek.
Investigating chemo’s effects on the brain
Lehtinen has conducted pioneering studies showing the importance of the CSF in promoting brain health and growth, together with the choroid plexus, the little-known brain tissue that produces CSF. Separately, Kanarek has been studying the metabolic effects of the chemotherapy drug methotrexate on cancer cells.
Methotrexate is used in children with acute lymphoblastic leukemia that has spread to the brain, as well as osteosarcoma and certain tumors of the central nervous system. It is also used in adults to treat leukemia, lymphoma, breast cancer, and lung cancer.
The two labs teamed up. In an initial study of mice, they found that exposure to methotrexate caused oxidative damage — a metabolic imbalance leading to the production of toxic oxygen molecules — to both the CSF and the choroid plexus. Nerve cells in the hippocampus, the brain’s main center of learning and memory, were also damaged. And in behavioral testing, the mice showed increased anxiety and impairment on tasks involving short-term learning and memory.
Using advanced laboratory tools, Lehtinen, Kanarek, and colleagues further showed that methotrexate prevented the choroid plexus from secreting a key enzyme, superoxide dismutase 3 (SOD3), into the CSF. SOD3 is a natural antioxidant that normally protects cells in the brain and other tissues by helping break down potentially toxic oxygen molecules.
The researchers think that without SOD3 delivered by the CSF, brain cells are more susceptible to damage.
Reversing toxic brain effects of methotrexate
Do the same effects happen in humans? The researchers first studied human neurons generated from stem cells. When they exposed the neurons to methotrexate, they produced less SOD and showed evidence of oxidative damage.
They also studied CSF samples from 11 adult cancer patients who had received methotrexate chemotherapy for lymphomas affecting their central nervous system. Compared with 12 cancer-free controls who did not receive methotrexate, these patients had reduced levels of SOD3 in their CSF and an increase in markers of oxidative damage.
So could adding SOD3 back protect the brain? Using a gene therapy approach in the mice, the research team boosted SOD3 production in the choroid plexus. When they then gave the mice methotrexate, the animals’ CSF and brain tissue were largely free of oxidative damage, and there was less evidence of anxiety and memory impairment.
“With more work in the future, these findings have the potential to prevent or treat one of the most concerning late effects of methotrexate, a cancer drug we use frequently,” says Diller, who was not part of the study.
Exploring treatment possibilities
Lehtinen and Kanarek now want to explore the effects of other chemotherapy drugs on the CSF and choroid plexus. They also want to better understand how methotrexate and antioxidants affect other parts of the brain, and test the efficacy of antioxidants given directly, rather than through gene therapy, in alleviating chemo brain.
Antioxidant treatments could potentially come in the form of an IV injection, a nasal spray, or an intrathecal injection, through a spinal tap, directly into the CSF. Such treatments could possibly be given together with the chemotherapy itself. The most immediate opportunity might be in patients who are receiving intrathecal methotrexate for brain cancer, or for leukemia or lymphoma with brain involvement, says Kanarek.
Another potential approach, yet to be tested, is simply providing antioxidants through antioxidant-rich foods or dietary supplements.
“This first study is just the tip of the iceberg,” says Lehtinen. “If we could correct the collateral damage of chemotherapy and make even a small improvement in the trajectory of patients’ lives, that would be really exciting.”
Ahram Jang, DPH, in the Lehtinen lab was first author on the paper.
Funding: The study was supported by the American Heart Association Pre-doctoral Fellowship Program, the National Institute of General Medical Sciences (T32 GM007753), The National Research Foundation of Korea, Boston Children’s Hospital, Gabrielle’s Angel Foundation for Cancer Research, STARR Cancer Consortium, the National Cancer Institute (1R01-CA222598), the Harvard Stem Cell Institute, the National Institute of Neurological Disorders and Stroke (R01 NS088566), the New York Stem Cell Foundation, and the Intellectual and Developmental Disabilities Research Center (1U54HD090255, P50HD105351).
Disclosure: Maria Lehtinen and Ahram Jang are co-inventors on a provisional patent application related to this paper.
About this chemotherapy and neuroscience research news
Author: Bethany Tripp
Source: Boston Children’s Hospital
Contact: Bethany Tripp – Boston Children’s Hospital
Image: The image is in the public domain
Original Research: Closed access.
“Choroid plexus-CSF-targeted antioxidant therapy protects the brain from toxicity of cancer chemotherapy” by Ahram Jang et al. Neuron
Choroid plexus-CSF-targeted antioxidant therapy protects the brain from toxicity of cancer chemotherapy
- MTX induces oxidative stress in mouse choroid plexus (ChP) and CSF
- MTX damages human neurons and diminishes anti-oxidative capacity of patient CSF
- ChP-targeted SOD3 gene therapy replenishes protective capacity of mouse CSF
- SOD3 gene therapy prevents MTX-induced lipid damage, anxiety, and memory deficits
For many cancer patients, chemotherapy produces untreatable life-long neurologic effects termed chemotherapy-related cognitive impairment (CRCI). We discovered that the chemotherapy methotrexate (MTX) adversely affects oxidative metabolism of non-cancerous choroid plexus (ChP) cells and the cerebrospinal fluid (CSF).
We used a ChP-targeted adeno-associated viral (AAV) vector approach in mice to augment CSF levels of the secreted antioxidant SOD3. AAV-SOD3 gene therapy increased oxidative defense capacity of the CSF and prevented MTX-induced lipid peroxidation in the hippocampus.
Furthermore, this gene therapy prevented anxiety and deficits in short-term learning and memory caused by MTX. MTX-induced oxidative damage to cultured human cortical neurons and analyses of CSF samples from MTX-treated lymphoma patients demonstrated that MTX diminishes antioxidant capacity of patient CSF.
Collectively, our findings motivate the advancement of ChP- and CSF-targeted anti-oxidative prophylactic measures to relieve CRCI.